Request Processed
Your registration request has been processed. We will contact you soon.
Register
First name
Last name
Email
Company
Toggle navigation
Toggle navigation
Login
Register
About
Contact Us
1
2
3
4
5
…
Next ›
Last »
Prevision Policy Clips | FDA Commissioner Califf Lauds Promise Of "Omics" Science But Stresses Need For "Oversight"
September 13, 2024
PBM Reform: Pending Proposals Viewed Skeptically By Academic Witnesses During House Hearing; Rare Voices Of Support For PBM Model On Capitol Hill
September 12, 2024
CDER Preparing To Expand “Integrated Review” Template To More Application Types, Wants Feedback On Possible Refinements To Documentation
September 12, 2024
Prevision Policy Clips | PBM Role Defended By Academic Witnesses
September 12, 2024
Oca-Leaving? Intercept Ocaliva Confirmatory Data in PBC Unpersuasive To FDA And Suggests Harm; Committee Vote Could Set Up “Streamlined” Withdrawal
September 11, 2024
Iterum’s Oral Sulopenem Likely To Receive Approval In Restricted uUTI Population Following Favorable Advisory Committee Discussion
September 11, 2024
Prevision Policy Clips | Medicare Drug Price Negotiation Is Briefly Mentioned In Presidential Debate
September 11, 2024
Refuse-To-File “Easily Correctable” Problems Added To Revised CBER SOPP; Document Says Center Will “Attempt To Rectify” Those Issues
September 10, 2024
CDER Quantitative Medicine “Center Of Excellence” Plans Repository Of Case Studies; Mission Emphasizes Education About QM Successes
September 10, 2024
Prevision Policy Clips | BIOSECURE Clears House September 9; 79 Democrats Vote “No”
September 10, 2024
Prevision Policy Clips | BIOSECURE Act Set To Pass House During “China Week”
September 9, 2024
Prevision Policy Clips | FDA Preparing To Expand “Integrated Review” Template To More Applications, Wants Feedback
September 6, 2024
Gene Therapy Transition From AAV Vectors To CRISPR-Edited Products Over The Next Decade Should Lower Costs And Expand Access, CBER’s Marks Predicts
September 5, 2024
Iterum’s Sulopenem Appears Headed To Approval: FDA Wants Public Discussion Of Warning Against Off Label Use Beyond Uncomplicated UTI
September 5, 2024
FDA Eager To “INTERACT” With Start-Ups: Webinar Emphasizes Range Of Meeting Opportunities, Enthusiasm Of Agency To Engage
September 5, 2024
Prevision Policy Clips | Stealth Bio Elamipretide For Barth Syndrome Set For Cardio-Renal Advisory Committee Review October 10
September 5, 2024
Prevision Policy Clips | FDA Updates Nitrosamine Guidance To Set August 1 Deadline For NDSRI Testing
September 4, 2024
Prevision Policy Clips | FDA Vaccines Office Deputy Is Karin Bok
September 3, 2024
Prevision Policy Clips | FDA Encourages A-syn Biomarker For Patient Selection in Parkinson’s
August 30, 2024
FDA Vaccine Office After COVID: Low-Profile, Experienced Leaders Underlie High-Profile Approvals
August 29, 2024
CDER Artificial Intelligence Council Will Catalogue & Coordinate AI Activities In The Center; Another Structural Move To Address Emerging Field
August 29, 2024
Prevision Policy Clips | House Oversight Chair James Comer (R-Ky.) Requests Hearing Testimony Correction From PBM Chief Executives
August 29, 2024
Prevision Policy Clips | Senate HELP Committee Chair Bernie Sanders Highlights Lilly Announcement To Lower Zepbound Starter Dose List Price
August 28, 2024
Advisory Committee Tracker: They’re Back! In-Person Meetings Resume And FDA Has Plenty On Tap; ODAC Will Look At Another PD-1 Labeling Issue
August 27, 2024
Prevision Policy Clips | Patient-Friendly Informed Consent Will Be Focus Of FDA Patient Engagement Advisory Committee Meeting October 30
August 27, 2024
1
2
3
4
5
…
Next ›
Last »